Brief: Reviva Pharmaceuticals Provides Update On Clinical Development Pipeline

Reviva Pharmaceuticals Holdings

27/07/2022 12:22

July 27 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA PHARMACEUTICALS PROVIDES UPDATE ON CLINICAL
DEVELOPMENT
PIPELINE
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - ANTICIPATES
INITIATING
TWO PHASE 2A TRIALS TARGETING ADHD AND PULMONARY ARTERIAL
HYPERTENSION IN Q4 2022
    * REVIVA PHARMACEUTICALS - ENROLLMENT REMAINS ON PACE FOR
REVIVA'S
PHASE 3 CLINICAL TRIAL FOR TREATMENT OF SCHIZOPHRENIA AT 15
SITES ACROSS US
    * REVIVA PHARMACEUTICALS - ENROLLMENT FOR PHASE 3 CLINICAL
TRIAL
FOR TREATMENT OF SCHIZOPHRENIA SET TO BEGIN AT SITES IN EUROPE
AND INDIA IN Q3 2022
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - TOP-LINE DATA FROM
RECOVER TRIAL IS EXPECTED IN MID-2023

Source text for Eikon:  ID:nGNX1gzhnL 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))